Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study

Mehta, 2020, COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet, 395, 1033, 10.1016/S0140-6736(20)30628-0 Lin, 2020, Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia, Emerg Microbes Infect, 9, 727, 10.1080/22221751.2020.1746199 Li, 2020, Coronavirus infections and immune responses, J Med Virol, 92, 424, 10.1002/jmv.25685 Conti, 2020, Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies, J Biol Regul Homeost Agents, 34 Zhang, 2020, The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality, Int J Antimicrob Agents, 105954, 10.1016/j.ijantimicag.2020.105954 Song, 2020, Emerging 2019 novel coronavirus (2019-nCoV) pneumonia, Radiology, 295, 210, 10.1148/radiol.2020200274 Chen, 2020, Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study, BMJ, 368, m1091, 10.1136/bmj.m1091 Sarzi-Puttini, 2020, COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?, Clin Exp Rheumatol, 38, 337, 10.55563/clinexprheumatol/xcdary Tang, 2020, Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia, J Thromb Haemost, 18, 844, 10.1111/jth.14768 Anderson, 2020, How will country-based mitigation measures influence the course of the COVID-19 epidemic?, Lancet, 395, 931, 10.1016/S0140-6736(20)30567-5 Red Nacional de Vigilancia Epidemiológica. Situación de COVID-19 en España. Informe 22 [Internet]. 2020. Available from: https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/INFORMES/Informes%20COVID-19/Informe%20n%C2%BA%2022.%20Situaci%C3%B3n%20de%20COVID-19%20en%20Espa%C3%B1a%20a%2013%20de%20abril%20de%202020.pdf. Wu, 2020, Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020, Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull, 25 Grein, 2020, Compassionate use of remdesivir for patients with severe Covid-19, N Engl J Med, 10.1056/NEJMoa2007016 Cao, 2020, A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19, N Engl J Med, 10.1056/NEJMoa2001282 Sheahan, 2020, Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV, Nat Commun, 11, 222, 10.1038/s41467-019-13940-6 Ferner, 2020, Chloroquine and hydroxychloroquine in covid-19, BMJ, 369, m1432, 10.1136/bmj.m1432 Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. ChinaXiv: 202003.00026v1. [Epub ahead of print]. Battegay, 2020, 2019-novel Coronavirus (2019-nCoV): estimating the case fatality rate: a word of caution, Swiss Med Wkly, 150 European Centre for Disease Prevention and Control. Coronavirus disease 2019 (COVID-19) in the EU/EEA and the UK – eighth update 2020. Available from: https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-coronavirus-disease-2019-covid-19-pandemic-eighth-update. Dougados, 2017, Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study, Ann Rheum Dis, 76, 88, 10.1136/annrheumdis-2016-210094 O'Shea, 2013, JAKs and STATs in immunity, immunodeficiency, and cancer, N Engl J Med, 368, 161, 10.1056/NEJMra1202117 Choy, 2019, The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib, Clin Exp Rheumatol, 37, 694 Li, 2003, Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus, Nature, 426, 450, 10.1038/nature02145 Richardson, 2020, Baricitinib as potential treatment for 2019-nCoV acute respiratory disease, Lancet, 395, e30, 10.1016/S0140-6736(20)30304-4 Stebbing, 2020, COVID-19: combining antiviral and anti-inflammatory treatments [published online ahead of print, 2020 Feb 27], Lancet Infect Dis Bernard, 1994, The American European Consensus Conference on ARDS, definitions, mechanisms, relevant outcomes, and clinical trial coordination, Am J Respir Crit Care Med, 149, 818, 10.1164/ajrccm.149.3.7509706 Guan, 2020, Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med, 10.1056/NEJMoa2002032 Chen, 2020, Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients, MedRxiv Casas-Rojo, 2020, Características clínicas de los pacientes hospitalizados con COVID-19 en España: resultados del Registro SEMI-COVID-19, Revista Clínica Española, 10.1016/j.rce.2020.07.003 Cantini, 2020, Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact, J Infect, 10.1016/j.jinf.2020.04.017 Cantini, 2020, Retrospective, multicenter study on the impact of baricitinib in COVID-19 moderate pneumonia, J Infect, 10.1016/j.jinf.2020.06.052